-
March 20, 2023 10:20 AM IST The company has received nod from the US Food & Drug Administration (USFDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the Mumbai-based drug maker said in a statement.
-
March 14, 2023 12:49 PM IST The company has received final approval from the US Food & Drug Administration (USFDA) for Clindamycin Hydrochloride Capsules, a generic version of Pfizer's Cleocin capsules, Glenmark Pharma said in a statement.
- March 09, 2023 10:18 AM IST
Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder.
- February 23, 2023 07:10 AM IST
Glenmark Pharma is on the verge of a breakout from a long consolidation period. The stock has also witnessed a fresh, built-up position in the F&O space.
- February 15, 2023 08:53 PM IST
Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 460 in its research report dated February 14, 2023.
- February 10, 2023 10:26 PM IST
Consolidated revenue was at Rs 3,463.9 crore, as against Rs 3,173.4 crore, up 9.2 per cent, Glenmark Pharmaceuticals said.
- January 23, 2023 11:36 AM IST
The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.
- January 17, 2023 02:20 PM IST
The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.
- January 10, 2023 10:58 AM IST
In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.
- December 22, 2022 06:49 AM IST
Biocon shares gained 3.5 percent at Rs 271 and formed long bullish candle on the daily charts with robust volumes. Also there was Morning Star kind of pattern formation, which is generally called as a bullish reversal pattern formed in an downtrend.
- December 21, 2022 10:18 AM IST
This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement.
- November 22, 2022 11:34 AM IST
ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 470 in its research report dated November 21, 2022.
- November 21, 2022 03:19 PM IST
Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 460 in its research report dated November 19, 2022.
- November 02, 2022 12:48 PM IST
The company has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Horizon Therapeutics' Buphenyl, the Mumbai-based drug maker said in a statement.
- October 26, 2022 09:59 PM IST
The drugs produced at the Baddi unit can now be detained without physical examination.
- October 20, 2022 12:27 PM IST
The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.
- October 06, 2022 12:36 PM IST
The Mumbai-based drug firm has launched the medication under the brand name LOBG and is priced at around Rs 10 per tablet.
- September 23, 2022 11:19 AM IST
Health Canada granted approval to partner Bausch Health Companies Inc and Glenmark Specialty SA, a subsidiary of the company, for Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), Glenmark Pharmaceuticals said in a statement.
- August 17, 2022 03:19 PM IST
ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 440 in its research report dated August 16, 2022.
- July 08, 2022 05:36 PM IST
Net Sales are expected to decrease by 4.2 percent Y-o-Y (down 5.9 percent Q-o-Q) to Rs 2,841.6 crore, according to Prabhudas Lilladher.
- June 28, 2022 10:49 AM IST
The acquisition by the company's fully-owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine, the company said in a statement.
- June 16, 2022 10:17 AM IST
The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet.
- April 25, 2022 11:18 AM IST
Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement.
- April 14, 2022 04:52 PM IST
Net Sales are expected to increase by 5.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs 3,006.1 crore, according to Prabhudas Lilladher.
- April 11, 2022 10:46 AM IST
Glenmark will initiate Phase 1 clinical trial in India by June 2022 for its small molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor
